Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Neuro-Oncology

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/neuonc/not006PMID 23410661PMCID PMC3661092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2‐Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

  2012cited by this paper
• The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

  2012cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cited by this paper
• IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival

  2012cited by this paper
• Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

  2012cited by this paper
• Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

  2012cited by this paper
• IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

  2012cited by this paper
• Altered Telomeres in Tumors with ATRX and DAXX Mutations

  2011cited by this paper
• Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology

  2011cited by this paper
• Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability

  2011cited by this paper
• Low-grade gliomas in adults.

  2011cited by this paper
• IDH1 mutations in gliomas: when an enzyme loses its grip.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.

  2010cited by this paper
• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

  2010cited by this paper
• IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010cited by this paper
• Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes

  2010cited by this paper
• Molecular classification of low-grade diffuse gliomas.

  2010cited by this paper
• Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  2009cited by this paper
• Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• The 2007 WHO classification of tumors of the central nervous system – what has changed?

  2008cited by this paper
• Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.

  2008cited by this paper
• Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

  2008cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Low-grade gliomas in adults

  2004cited by this paper
• Surgical resection for patients with benign primary brain tumors and low grade gliomas

  2004cited by this paper
• Promises and controversies in the management of low-grade glioma.

  2003cited by this paper
• Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.

  2001cited by this paper
• Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

  2000cited by this paper
• Sensitivity of metabolic fluxes to covalent control.

  1985cited by this paper
• THE CANCER CELL

  1924cited by this paper

• Mass Spectrometry Advances in Analysis of Glioblastoma

  2024cites this paper
• Non-Invasive Detection of the IDH-1 Gene Mutation in Cerebral Gliomas Based on Proton MR Spectroscopy

  2024cites this paper
• Non-invasive detection of IDH-1 mutation in brain gliomas based on proton MR spectroscopy

  2024cites this paper
• Integrated machine learning survival framework develops a prognostic model based on inter-crosstalk definition of mitochondrial function and cell death patterns in a large multicenter cohort for lower-grade glioma

  2023cites this paper
• Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma

  2023cites this paper
• Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours

  2022cites this paper
• Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas

  2022cites this paper
• Der diagnostische Stellenwert der Isocitrat-Dehydrogenase-Mutationen beim Chondrosarkom

  2022cites this paper
• Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review.

  2021cites this paper
• Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.

  2021cites this paper
• Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma

  2020cites this paper
• Development and application of analytical tools to study the origin, fate and impact of the oncometabolite 2-hydroxyglutarate and its lactone

  2020cites this paper
• Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis

  2019cites this paper
• Novel methods in adrenal research: a metabolomics approach

  2019cites this paper
• Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin

  2019cites this paper
• IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy

  2018cites this paper
• Molecular pathogenesis and therapeutic implications in pediatric high‐grade gliomas

  2017cites this paper
• Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas

  2017cites this paper
• Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status

  2017cites this paper
• Development of a LC-MS/MS Method for the Simultaneous Detection of Tricarboxylic Acid Cycle Intermediates in a Range of Biological Matrices

  2017cites this paper
• 2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T

  2017cites this paper
• Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

  2016cites this paper
• Metabolic consequences of oncogenic IDH mutations.

  2015cites this paper
• Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas

  2015cites this paper
• [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].

  2015cites this paper
• Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.

  2014cites this paper
• IDH mutation in glioma: new insights and promises for the future.

  2014cites this paper
• IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma

  2014cites this paper
• D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

  2014cites this paper
• Is there pseudoprogression in secondary glioblastomas?

  2013cites this paper
• What do we know about IDH1/2 mutations so far, and how do we use it?

  2013cites this paper
• Antagonistic functional duality of cancer genes.

  2013cites this paper